Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Pharmaceuticals
- Disease
- Technical Know How
- Drug Discovery
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2659
Savvy ® (C31G vaginal gel) is a potential microbicide for the prevention of male-to-female transmission of HIV among women at high risk of infection. The active compound in Savvy is C31G, a broad-spectrum compound with antiviral, antibacterial and antifungal activity.
Product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally, including Savvy®, which underwent Phase 3 clinical trials in Ghana and Nigeria for reduction in the transmission of Human Immunodeficiency Virus/Acquired Immunodeficiency Disease, or HIV/AIDS, both of which were suspended in 2005 and 2006 and terminated before completion, and is the subject to a Phase 3 contraception trial in the United States. While the Savvy Phase 3 contraception trial in the United States has been completed and the analysis of the results is expected to be completed by the end of 2009.
IPSCIO Record ID: 1206
The Development and License Agreement has been amended several times; most recently in March 2007, the Agreement was amended to cover only the development and commercialization of Fuzeon.
The Licensor is a biopharmaceutical company primarily engaged in the commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, our first commercial product and our development-stage compound offer a novel mechanism of action to treat and potentially prevent the transmission of HIV.
IPSCIO Record ID: 362526
The Licensor Clinical Trials Unit located in London has recognized expertise in the field of clinical trials with the overall objective of developing effective preventive and therapeutic interventions for HIV infection in adults and children.
Licensee has developed a topical formulation of its naphthalene sulphonic acid formaldehyde condensate antiviral product, which formulation is under evaluation as a topical microbicide for the prevention of HIV infection, and Licensor desires that Product shall be included in the Phase Ill Clinical Trial included in the Program and in consideration thereof is willing to supply its product and matching placebo to the clinical centers participating in the Phase Ill Clinical Trial and is willing to have Product evaluated in the Phase Ill Clinical Trial under the terms and conditions set out in this Agreement.
IPSCIO Record ID: 253
Product relates to brand name Fuzeon® in indications other than the treatment of HIV. Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product. Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41. The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.
Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021
IPSCIO Record ID: 28080
